Benznidazole with CCNU: a clinical phase I toxicity study.

[1]  N. Bleehen,et al.  A phase I study of the combination of benznidazole and CCNU in man. , 1984, International journal of radiation oncology, biology, physics.

[2]  R. Murphy,et al.  Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans. , 1983, British Journal of Cancer.

[3]  C. Coleman,et al.  Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. , 1983, Cancer research.

[4]  P. Workman,et al.  Chemosensitization by lipophilic nitroimidazoles. , 1983, British Journal of Cancer.

[5]  D. Hirst,et al.  Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. , 1983, Cancer research.

[6]  D. Siemann,et al.  In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole. , 1983, Cancer research.

[7]  P. Workman,et al.  Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. , 1982, British Journal of Cancer.

[8]  R. Comis,et al.  The pulmonary toxicity of antineoplastic agents. , 1982, Seminars in oncology.

[9]  R. Schilsky.  Renal and metabolic toxicities of cancer chemotherapy. , 1982, Seminars in oncology.

[10]  D. Siemann.  The response of mouse lung tumors to combinations of CCNU and misonidazole. , 1982, International journal of radiation oncology, biology, physics.

[11]  J. Brown,et al.  The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles. , 1982, International journal of radiation oncology, biology, physics.

[12]  N. J. McNally,et al.  Enhancement of chemotherapy agents. , 1982, International journal of radiation oncology, biology, physics.

[13]  W. Ziegler,et al.  Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. , 1979, Arzneimittel-Forschung.

[14]  B. Hoogstraten,et al.  CCNU (1‐[2‐chloroethyl]‐3‐cyclohexyl‐1‐nitrosourea, NSC‐79037) in the treatment of cancer. Phase II study , 1973, Cancer.